Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

“We are thrilled to see these data, which demonstrate conclusively that the Accelerate PhenoTest™ BC kit positively impacts clinical outcomes across a diverse set of institutions and patient populations. The studies show an improvement in antibiotic use, a necessary factor for lowering the risk of multidrug-resistant infections and in preserving the patient’s vital functions, while also improving the hospital’s bottom line by reducing patient length of stay,” commented Dr. Romney Humphries, Chief Scientific Officer of Accelerate Diagnostics and former UCLA Section Chief for Clinical Microbiology.